Total and high molecular weight adiponectin in patients with coronary artery disease.
BACKGROUND
Serum adiponectin inversely correlates with the extent of coronary artery disease (CAD).


OBJECTIVE
To investigate the clinical significance of measuring high molecular weight (HMW) adiponectin in addition to total adiponectin from different samples (peripheral veins and ostia of coronary arteries) in patients with CAD.


METHODS
We studied 134 patients; 57 with acute coronary syndrome (ACS), 44 with stable angina and 33 healthy patients. Total and HMW adiponectin were measured in the coronary ostia and peripheral veins simultaneously. Venous levels of lipid profile, C-reactive protein, tumour necrosis factor-alpha, interleukin-6 and insulin were measured.


RESULTS
Mean levels of HMW adiponectin in the coronary ostia were significantly correlated with the venous levels of total (r = 0.33, P = 0.002) and HMW (r = 0.37, P = 0.002) adiponectin. Mean levels of total and HMW adiponectin were lower in CAD patients versus controls (6.9 +/- 0.5 versus 7.9 +/- 0.7 microg/ml, P = 0.3 and 1.9 +/- 0.2 versus 3.1 +/- 0.3 microg/ml, P = 0.003). In the coronary ostia, levels of HMW adiponectin were higher in ACS than those with stable angina (1.1 +/- 0.1 versus 0.8 +/- 0.1 microg/ml, P = 0.2). In patients with CAD, levels of ostial adiponectin (total and HMW) were significantly lower in diabetic than non-diabetic patients (6.5 +/- 0.8 versus 9.4 +/- 1.1 microg/ml, P = 0.04 and 0.8 +/- 0.12 versus 1.2 +/- 0.1 microg/ml, P = 0.03). Mean levels of venous adiponectin (total and HMW) were non-significantly lower in diabetic patients (5.9 +/- 0.7 versus 7.7 +/- 0.7, P = 0.12 and 1.8 +/- 0.4 versus 1.9 +/- 0.1, P = 0.8).


CONCLUSIONS
Measurement of HMW adiponectin and its ratio to total adiponectin may be a better marker for CAD than total adiponectin levels. Ostial levels of adiponectin in ACS may indicate re-distribution of adiponectin molecules towards the acute lesions. The low HMW adiponectin levels in diabetes mellitus may in part explain the worse outcome of CAD in diabetics.
El-Menyar
Ayman
A
Department of Cardiology and Cardiovascular Surgery, Qatar.
Rizk
Nasser
N
Al Nabti
Abdulrahman D
AD
Hassira
Sana Abu
SA
Singh
Rajvir
R
Abdel Rahman
Mohamed Osman
MO
Suwaidi
Jassim Al
JA
D054058:Acute Coronary Syndrome / Q000097:blood* / Q000209:etiology / Q000503:physiopathology; D052242:Adiponectin / Q000097:blood; D000328:Adult; D000787:Angina Pectoris / Q000097:blood* / Q000209:etiology / Q000503:physiopathology; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000032:analysis; D003324:Coronary Artery Disease / Q000097:blood* / Q000150:complications / Q000503:physiopathology; D003430:Cross-Sectional Studies; D048909:Diabetes Complications / Q000097:blood* / Q000503:physiopathology; D005260:Female; D006801:Humans; D007328:Insulin / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D008970:Molecular Weight; D011237:Predictive Value of Tests; D012720:Severity of Illness Index; D013318:Stroke Volume; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
C499918:ADIPOQ protein, human; D052242:Adiponectin; D015415:Biomarkers; C508600:IL6 protein, human; D007328:Insulin; D015850:Interleukin-6; D008055:Lipids; D014409:Tumor Necrosis Factor-alpha; D002097:C-Reactive Protein